Cargando…

Esophageal cancer treated by endoscopic submucosal dissection after neoadjuvant chemoradiotherapy: a case report

INTRODUCTION: The treatment of esophageal cancer remains clinically challenging because of the overall poor prognosis associated with the disease. The mortality rate associated with surgical treatment is high, and the majority of diagnosed patients are old. As such, surgery is not possible in many c...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Jang Hwan, Lee, Sang Ah, Kang, Gyoun Eun, Kim, Jong Min, Park, Jin Kyung, Chung, Yun Jin, Jung, Jae Kwon, Park, Chang Keun, Kim, Hyun Soo, Lee, Dong Wook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302077/
https://www.ncbi.nlm.nih.gov/pubmed/25519497
http://dx.doi.org/10.1186/1752-1947-8-439
Descripción
Sumario:INTRODUCTION: The treatment of esophageal cancer remains clinically challenging because of the overall poor prognosis associated with the disease. The mortality rate associated with surgical treatment is high, and the majority of diagnosed patients are old. As such, surgery is not possible in many cases, even when the cancer has progressed to a resectable state. CASE PRESENTATION: We present the case of an 82-year-old Korean man who presented to our institution with intermittent odynophagia. Esophageal cancer with submucosal invasion and metastasis to three regional lymph nodes was diagnosed. After neoadjuvant chemoradiotherapy, his regional lymph nodes disappeared. Because of his poor pulmonary function, surgical treatment could not be performed. Endoscopic submucosal dissection was carried out instead, and endoscopic triamcinolone injections were performed serially. Neither recurrence nor abnormal symptoms such as dysphagia or regurgitation have developed for 36 months. CONCLUSIONS: The literature suggests that endoscopic submucosal dissection after chemoradiotherapy is a viable treatment modality in patients with esophageal cancer with a high surgical treatment risk.